---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-002401"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-01-27T23:59:59+00:00"
generated_at: "2026-06-27T14:38:41.291908+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Interpace appoints Vijay Aggarwal to Board, replacing Eric Lev effective Feb 1, 2022

## Summary
- Eric B. Lev resigns as director effective Feb 1, 2022; no disagreement with the Company.
- Vijay Aggarwal appointed to Board effective Feb 1, 2022 as Class I director.
- Aggarwal will Chair Regulatory Compliance Committee and serve on Nominating & Corporate Governance Committee.
- Compensation: $50k annual director fee ($40k base + $10k committee chair) plus option for 28k shares.
- Aggarwal has 30+ years in diagnostics/pharma; previously CEO of Vaxigenix, President of Aureon Labs.

## SEC filing metadata
- accession: 0001493152-22-002401
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-01-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/0001493152-22-002401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-002401
- JSON: https://secwatch.observer/filing/0001493152-22-002401.json
- Plain text: https://secwatch.observer/filing/0001493152-22-002401.txt

## Key facts
- Executive change
  Vijay Aggarwal was appointed as Director at INTERPACE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Director
  source text: Dr. Vijay Aggarwal as a director to replace Mr. Lev on the Company's Board, effective February 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/0001493152-22-002401-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.